U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07900633) titled 'A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk' on Oct. 22.
Brief Summary: The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Intervention:
DRUG: Eloralintide
Administered SC
DRUG: Placebo
Administered SC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: E...